ERBB2

Biomarkers

ERBB2 is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
ERBB2 TKD activating variants	Somatic Variant	2	2
ERBB2 oncogenic variants	Somatic Variant	1	2
ERBB2 amplification	Copy Number	18	23

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Zongertinib
FDA (1)	ERBB2 TKD activating variants	Lung Non-Squamous Non-Small Cell Carcinoma	Sevabertinib
EMA (1) FDA (1)	ERBB2 oncogenic variants	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
EMA (3)	ERBB2 amplification	Invasive Breast Carcinoma	Docetaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab deruxtecan
EMA (1)	ERBB2 amplification	Non-Small Cell Lung Cancer	Trastuzumab deruxtecan
EMA (1)	ERBB2 amplification	Adenocarcinoma of the Gastroesophageal Junction	Trastuzumab deruxtecan
EMA (2)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab
EMA (2)	ERBB2 amplification	Invasive Breast Carcinoma	Paclitaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Anastrozole, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Carboplatin, Docetaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Doxorubicin, Paclitaxel, Trastuzumab
EMA (1)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Capecitabine, Cisplatin, Trastuzumab
EMA (1)	ERBB2 amplification	Esophagogastric Adenocarcinoma	Cisplatin, Fluorouracil, Trastuzumab
EMA (2)	ERBB2 amplification	Invasive Breast Carcinoma	Trastuzumab emtansine
EMA (1)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
EMA (1)	ER positive, ERBB2 amplification	Invasive Breast Carcinoma	Neratinib
EMA (1)	ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Neratinib
EMA (1)	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib
EMA (1)	ER positive, ERBB2 amplification, PR negative	Invasive Breast Carcinoma	Lapatinib, Trastuzumab
EMA (1)	ER positive, ERBB2 amplification, PR positive	Invasive Breast Carcinoma	Lapatinib, Letrozole